Conveniently, effects on Aβ deposition could be measured early through analysis of several AD biomarkers, such as amyloid positronic emission tomography (PET), cerebrospinal fluid (CSF)-Aβ (42) and CSF tau levels in patients80. Here, MAPT is linked to Alzheimer disease.